Elite Pharmaceuticals, Inc. (ELTP)
0.2498
0.00 (0.00%)
USD |
OTCM |
Oct 23, 16:00
Elite Pharmaceuticals Enterprise Value : 235.70M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 235.70M |
| October 22, 2026 | 233.22M |
| October 21, 2026 | 230.53M |
| October 20, 2026 | 230.80M |
| October 19, 2026 | 236.74M |
| October 16, 2026 | 240.49M |
| October 15, 2026 | 240.25M |
| October 14, 2026 | 235.05M |
| October 13, 2026 | 241.30M |
| October 12, 2026 | 241.30M |
| October 09, 2026 | 241.41M |
| October 08, 2026 | 252.07M |
| October 07, 2026 | 240.52M |
| October 06, 2026 | 230.53M |
| October 05, 2026 | 207.96M |
| October 02, 2026 | 212.92M |
| October 01, 2026 | 211.14M |
| September 30, 2026 | 227.08M |
| September 29, 2026 | 224.07M |
| September 28, 2026 | 237.42M |
| September 25, 2026 | 244.66M |
| September 24, 2026 | 232.45M |
| September 23, 2026 | 234.73M |
| September 22, 2026 | 232.63M |
| September 21, 2026 | 227.51M |
| Date | Value |
|---|---|
| September 18, 2026 | 233.22M |
| September 17, 2026 | 235.81M |
| September 16, 2026 | 230.53M |
| September 15, 2026 | 234.52M |
| September 14, 2026 | 246.47M |
| September 11, 2026 | 249.92M |
| September 10, 2026 | 237.10M |
| September 09, 2026 | 243.56M |
| September 08, 2026 | 246.58M |
| September 04, 2026 | 244.53M |
| September 03, 2026 | 247.87M |
| September 02, 2026 | 264.14M |
| September 01, 2026 | 273.29M |
| August 31, 2026 | 276.31M |
| August 28, 2026 | 277.76M |
| August 27, 2026 | 276.85M |
| August 26, 2026 | 273.62M |
| August 25, 2026 | 274.69M |
| August 24, 2026 | 278.03M |
| August 21, 2026 | 284.39M |
| August 20, 2026 | 287.03M |
| August 19, 2026 | 293.00M |
| August 18, 2026 | 293.54M |
| August 17, 2026 | 298.39M |
| August 14, 2026 | 300.54M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Daré Bioscience, Inc. | 3.945M |
| Eton Pharmaceuticals, Inc. | 1.417B |
| ANI Pharmaceuticals, Inc. | 1.903B |
| Corcept Therapeutics, Inc. | 8.967B |
| Veru, Inc. | 15.08M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 5.911M |
| Revenue (Quarterly) | 32.36M |
| Total Expenses (Quarterly) | 26.44M |
| EPS Diluted (Quarterly) | 0.0052 |
| Gross Profit Margin (Quarterly) | 40.61% |
| Profit Margin (Quarterly) | 18.27% |
| Earnings Yield | 10.53% |
| Operating Earnings Yield | 12.77% |
| Normalized Earnings Yield | 3.243 |